Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$4.91 ▼ -0.05
(-1.01%)
MKT CAP: $46.3M • VOL: 162.1K
52W L $2 52W H $14
ROARABLE / RQD
D- • 42/100
PIOTROSKI
2 / 9
LONA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$102.3M | -$100.9M | -$125.5M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$106.0M | -$97.0M | -$117.7M |
| EBITDA (Normalized) | — | -$100.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$45.7M | -$97.2M | -$100.8M |
| Capital Expenditures (CapEx) | — | $33.0K | — |
| Free Cash Flow (FCF) | -$45.7M | -$97.2M | -$100.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $69.3M | $48.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $27.8M | $44.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LONA.